| Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan. We show 56 historical shares outstanding datapoints in our EXEL shares outstanding history coverage, used to compute EXEL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EXEL market cap history over the course of time is important for investors
interested in comparing EXEL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EXEL versus a peer is one thing; comparing
EXEL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EXEL can fluctuate over the course of history.
With this page we aim to empower investors researching EXEL by allowing them to research the EXEL market cap history.